Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

Part of paid clinical trials in Fairway, Kansas.

Sponsor
Jun Zhang, MD, PhD
Study ID
NCT05332925
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 110 Years
Healthy Volunteers
Not accepted

Interventions

  • Standard of care immune checkpoint inhbitors — DRUG
    This is NOT an interventional study.

Study Details

To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.

Key Dates

Start date
Jul 21, 2022
Status verified
Feb 2024
Primary completion
Jan 31, 2026
Completion
Feb 28, 2027

Study Design

Enrollment
25 participants (estimated)

Primary Outcome Measure

Feasibility of establishing 3D ex-vivo tumoroid model [ Time Frame: 2 years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
The University of Kansas Cancer Center (KUCC)FairwayKansas66205
Clinical Trials Nurse Navigator
[email protected]
913-945-7552
Steve Williamson, MD
[email protected]
913-588-3808
The University of Kansas Cancer Center, Westwood CampusKansas CityKansas66205
Clinical Trials Nurse Navigator
[email protected]
913-945-7552

Find similar trials in Fairway, KS

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
The University of Kansas Cancer Center (KUCC)· Fairway, KSThe University of Kansas Cancer Center, Westwood Campus· Kansas City, KS

Related Studies